NEW YORK (360Dx) – A team of industry players and a Japanese government agency on Monday announced a collaboration leveraging exosomes to improve cancer diagnosis and treatment.
The collaboration is being carried out by the National Cancer Center Japan, JVCKENWOOD, Sysmex, and Daiichi Sankyo, and aims to detect cancer-specific exosomes from patients' blood. The collaborators said that the effort is expected to provide patients with additional therapy options, as well as a new approach to tumor tissue sampling. The work is expected to reduce the stress of patients by eliminating the need for multiple biopsies, they added.
JVCKENWOOD will leverage its exosome measurement device to build technologies for detecting cancer-specific exosomes, which will then be evaluated by Sysmex, who will also apply its proprietary gene and protein measurement technologies for clinical use.
Finally, the National Cancer Center Japan and Daiichi Sankyo will leverage exosome measurement data to improve the diagnosis and treatment of patients, they said.